Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8754251 | 0.87 | ALDH1A1 (0.56) | ALDH1A1CYP2A6SMN1; SMN2MAPTHPGD | |
| SCHEMBL14996346 | 0.86 | ALDH1A1 (0.76) | ALDH1A1CYP2A6SMN1; SMN2MAPTHPGD | |
| SCHEMBL1524953 | 0.85 | ALDH1A1 (0.52) | ALDH1A1CYP2A6SMN1; SMN2MAPTHPGD | |
| SCHEMBL657580 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP2A6SMN1; SMN2MAPTHPGD | |
| SCHEMBL4693722 | 0.83 | RELA (0.53) | MAPTPTPN1 | |
| SCHEMBL12567393 | 0.83 | RELA (0.53) | MAPTPTPN1 | |
| SCHEMBL4693719 | 0.83 | RELA (0.53) | MAPTPTPN1 | |
| Propene SCHEMBL10513668 | 0.82 | ALDH1A1 (0.42) | ALDH1A1CYP2A6SMN1; SMN2MAPTHPGD | |
| SCHEMBL3589633 | 0.82 | NQO1 (0.50) | MAPTKDM4E | |
| SCHEMBL246323 | 0.82 | ALDH1A1 (0.61) | ALDH1A1CYP2A6SMN1; SMN2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027243-A1 | AMPHIPHILIC COMPOUNDS FOR ATTENUATING NEUROTOXICITY OF AMYLOID-beta OLIGOMERS AND DIAGNOSTIC METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4630413-A1 | FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | Firmenich Incorporated (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250221944-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | KBLUEBIO INC (KR) | 2025-07-10 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250134146-A1 | FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | FIRMENICH INCORPORATED (US) | 2025-05-01 | — | — | US | disclosed |
| CN-115697980-B | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250090565-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YewSavin, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| CN-119504685-A | Benzopyran flavonoid compound, preparation method and application thereof, and pharmaceutical preparation | 南开大学 | 2025-02-25 | — | — | CN | disclosed |
| EP-4506328-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | KBlueBio Inc (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-5106871-A | Reduced side effects | TSUMURA & CO. (JP) | 1992-04-21 | — | — | US | disclosed |
| CN-1036795-A | PEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 1989-11-01 | — | — | CN | disclosed |
| EP-0336230-A2 | Cyclic peptide antagonists of Substance P and Substance K | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |
| EP-0292576-A1 | ANTI-ULCEROUS AGENT CONTAINING CHALCONE DERIVATIVE AS EFFECTIVE INGREDIENT AND NOVEL CHALCONE DERIVATIVES | TSUMURA & CO. (JP) | 1988-11-30 | — | — | EP | disclosed |
| EP-0057162-B1 | PROCESS FOR THE PRODUCTION OF IMAGES | CIBA-GEIGY AG (CH) | 1984-06-27 | — | — | EP | disclosed |
| US-4368253-A | Image formation process | CIBA-GEIGY CORPORATION (US) | 1983-01-11 | — | — | US | disclosed |
| EP-0057162-A1 | Process for the production of images | CIBA-GEIGY AG (CH) | 1982-08-04 | — | — | EP | disclosed |
| US-4327088-A | ANTIVIRAL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1982-04-27 | — | — | US | disclosed |
| EP-0021000-A2 | Substituted acetophenones, their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-01-07 | — | — | EP | disclosed |
| US-3987105-A | PROCESS FOR METHOXYMETHYLATION OF PHENOLIC HYDROXYL GROUPS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027243-A1 | AMPHIPHILIC COMPOUNDS FOR ATTENUATING NEUROTOXICITY OF AMYLOID-beta OLIGOMERS AND DIAGNOSTIC METHODS | APP, BACE1, PSEN1 | ALDH1A1 2948/4885CYP2A6 4421/4885SMN1; SMN2 427/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ALDH1A1 3285/4885CYP2A6 670/4885SMN1; SMN2 3415/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ALDH1A1 3081/4885CYP2A6 1665/4885SMN1; SMN2 4161/4885 |
| US-20250090565-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, TFPI, SERPINE1 | ALDH1A1 2859/4885CYP2A6 1473/4885SMN1; SMN2 4155/4885 |
| US-20250221944-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | MCL1, CRBN, BCL3 | ALDH1A1 1814/4885CYP2A6 2119/4885SMN1; SMN2 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.